Targeting miRNA by CRISPR/Cas in cancer: advantages and challenges

Area of Science:

• Biomedical Sciences
• Genetics
• Oncology

Background:

• The CRISPR/CRISPR-associated protein (Cas) system has revolutionized biomedical research over the past decade.
• CRISPR/Cas technology provides novel approaches to understanding cancer, including the noncoding genome, tumor heterogeneity, and precision medicine.

Purpose of the Study:

• To highlight cutting-edge CRISPR/Cas-based gene-editing therapies targeting microRNAs (miRNAs) for cancer treatment.
• To discuss the challenges associated with CRISPR/Cas-mediated miRNA gene editing in cancer therapy.
• To present advanced strategies for overcoming these challenges and developing safe, effective cancer gene-editing therapies.

Main Methods:

• Review of current CRISPR/Cas gene-editing technologies applicable to cancer therapy.
• Analysis of strategies for targeting microRNAs (miRNAs) using CRISPR/Cas systems.
• Evaluation of safety considerations and potential abnormalities associated with CRISPR/Cas gene editing.

Main Results:

• CRISPR/Cas technology enables precise targeting of mutations and microRNAs (miRNAs) for cancer therapy.
• Effective and safe cancer gene-editing therapy development requires careful design to avoid harming normal cells.
• Advanced strategies are being developed to address challenges in CRISPR/Cas-mediated miRNA gene editing.

Conclusions:

• CRISPR/Cas-based gene editing holds significant promise for developing novel cancer therapies targeting miRNAs.
• Overcoming challenges related to safety and efficacy is crucial for the clinical translation of these therapies.
• Further research into advanced strategies will pave the way for safer and more effective miRNA-targeted cancer treatments.